Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial

Acta Oncologica

Volumn 51, Issue 6, 2012, Pages 713-721

  Matthiessen, Louise Wichmann ^a   Johannesen, Helle Hjorth ^a   Hendel, Helle Westergren ^a   Moss, Timothy ^b   Kamby, Claus ^c   Gehl, Julie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLEEDING; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ELECTROCHEMOTHERAPY; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYPERPIGMENTATION; INFECTION; LUNG DIFFUSION CAPACITY; MASTECTOMY; NAUSEA; ODOR; PAIN; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; ULCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ELECTROCHEMOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84863860429     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.685524     Document Type: Article

References (24)

1. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-106.
2. Solin LJ, Harris EE, Orel SG, Glick J. Local-regional recurrence after breast conserving treatment or mastectomy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
3. Clemons M, Hamilton T, Goss P. Does treatment at the time of locoregional failure of breast cancer alter prognosis? Cancer Treat Rev 2001;27:83-97. (Pubitemid 32499381)
4. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: An improved method for screening drugs. Anti-Cancer Drugs 1998;9:319-25. (Pubitemid 28241821)
5. Orlowski S, Belehradek Jr J, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988;37:4727-33. (Pubitemid 19006314)
6. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003;29:371-87. (Pubitemid 37185104)
7. Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009;16:191-9.
8. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy, an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Supplements 2006;4:3-13. (Pubitemid 44755131)
9. Curatolo P, Quaglino P, Marenco F, Mancini M, Nardo T, Mortera C, et al. Electrochemotherapy in the treatment of kaposi sarcoma cutaneous lesions: A two-center prospective phase II trial. Ann Surg Oncol Epub 2011 Aug 6.
10. Matthiessen LW, Chalmers RL, Sainsbury DC, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011;50:621-9.
11. Whelan MC, Larkin JO, Collins CG, Cashman J, Breathnach O, Soden DM, et al. Effective treatment of an extensive recurrent breast cancer which was refractory to multimodal therapy by multiple applications of electrochemotherapy. EJC Supplements 2006;4:32-4. (Pubitemid 44666528)
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. Carr T, Moss T, Harris D. The DAS24: A short form of the Derriford Appearance Scale DAS59 to measure individual responses to living with problems of appearance. Br J Health Psychol 2005;10:285-98. (Pubitemid 40677065)
14. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Supplements 2006;4:14-25. (Pubitemid 44755132)
15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
16. Ohnuma T, Holland JF, Masuda H, Waligunda JA, Goldberg GA. Microbiological assay of bleomycin: Inactivation, tissue distribution, and clearance. Cancer 1974;33:1230-8.
17. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008;98:388-98. (Pubitemid 351161255)
18. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: Characterization and consequences for drug and gene delivery. Biochim Biophys Acta 2002;1569:51-8. (Pubitemid 34165557)
19. Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 2000;10:585-9. (Pubitemid 32011982)
20. Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008;15:2215-22.
21. Domenge C, Orlowski S, Luboinski B, De BT, Schwaab G, Belehradek J, Jr., et al. Antitumor electrochemotherapy: New advances in the clinical protocol. Cancer 1996;77:956-63. (Pubitemid 26061292)
22. Mathes DD. Bleomycin and hyperoxia exposure in the operating room. Anesth Analg 1995;81:624-9.
23. Agerholm-Larsen B, Iversen HK, Ibsen P, Moller JM, Mahmood F, Jensen KS, et al. Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. Cancer Res 2011;71:3753-62.
24. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. Electrochemotherapy: A new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011;10:475-85.